Species differences in mechanism-based inactivation of CYP3A in humans, rats and mice

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 1, 2010, Pages 93-100

  Aueviriyavit, Sasitorn ^a   Kobayashi, Kaoru ^a   Chiba, Kan ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

CYP3A; Humans; Mechanism based inactivation; Mice; Rats; Species differences

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 3A; DILTIAZEM; ERYTHROMYCIN; NICARDIPINE; TRIAZOLAM; TROLEANDOMYCIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; ENZYME INACTIVATION; ENZYME SPECIFICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; RAT; SPECIES DIFFERENCE;

EID: 77949287707     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.25.93     Document Type: Article

References (28)

1. Zhang, Z. and Wong, Y. N.: Enzyme kinetics for clinically relevant CYP inhibition. Curr. Drug Metab., 6: 241-257 (2005).
2. Grimm, S.W., Einolf, H. J., Hall, S. D., He, K., Lim, H., Ling, K. J., Lu, C., Nomeir, A. A., Seibert, E., Skordos, K. W., Tonn, G. R., Horn, R. V., Wang, R. W., Wong, Y. N., Yang, T. J. and Obach, R. S.: The conduct of in vitro studies to address timedependent inhibition of drug-metabolizing enzymes: A perspective of the pharmaceutical research and manufacturers of America. Drug Metab. Dispos., 37: 1355-1370 (2009).
3. Zhou, S., Chan, S. Y., Goh, B. C., Chan, E., Duan, W., Huang, M. and McLeod, H. L.: Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet., 44: 279-304 (2005).
4. Zhou, S.: Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4. Curr. Pharm. Des., 14: 990-1000 (2008).
5. Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R. and Ball, S. E.: Drugdrug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation of typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos., 32: 1201-1208 (2004).
6. McGinnity, D. F., Berry, Am. J., Kenny, J. R., Grime, K. and Riley, R. J.: Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab. Dispos., 34: 1291-1300 (2006).
7. Kanamitsu, S., Ito, K., Green, C. E., Tyson, C. A., Shimada, N. and Sugiyama, Y.: Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm. Res., 17: 419-426 (2000).
8. Ito, K., Ogihara, K., Kanamitsu S. and Itoh T.: Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab. Dispos., 31: 945-954 (2003).
9. Mayhew, B. S., Jones, D. R. and Hall, S. D.: An in vitro model for prediction in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos., 28: 1031-1037 (2000).
10. Polasek, T. M. and Miners, J. O.: Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P450 3A substrate. Eur. J. Clin. Pharmacol., 62: 203-208 (2006).
11. Yamano, K., Yamamoto, K., Katashima, M., Kotaki, H., Takedomi, S., Matsuo, H., Ohtani, H., Sawada, Y. and Iga, T.: Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metab. Dispos., 29: 443-452 (2001).
12. Kobayashi, K., Urashima, K., Shimada, N. and Chiba, K.: Substrate specificity for rat Cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem. Pharmacol., 63: 889-896 (2002).
13. Eagling, V. A., Tjia, J. F. and Back, D. J.: Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol., 45: 107-114 (1998).
14. Turpeinen, M., Ghiciuc, C., Opritioui, M., Tursas, L., Pelkonen, O. and Pasanen, M.: Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: A comparative study in vitro. Xebobiotica, 37: 1367-1377 (2007).
15. van Herwaarden, A. E., Wagenaar, E., van der Kruijssen, C. M., van Waterschoot, R. A., Smit, J.W., Song, J. Y., van der Valk, M. A., van Tellingen, O., van der Hoorn, J. W., Rosing, H., Beijnen, J. H. and Schinkel, A. H.: Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J. Clin. Invest., 117: 3583-3592 (2007).
16. Ma, X., Cheung, U., Krausz, K. W., Shah, Y. M., Wang, T., Idle, J. R. and Gonzalez, F. J.: A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab. Dispos., 36: 2506-2512 (2008).
17. Franklin, M. R.: Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol., 206: 559-573 (1991).
18. Olkkola, K. T., Aranko, K., Luurila, H., Hiller, A., Saarnivaara, L., Himberg, J. J. and Neuvonen, P. J.: A potentially hazardous interaction between erythromycin and midazolam. Clin. Pharmacol. Ther., 53: 298-305 (1993).
19. Ma, B., Prueksaritanont, T. and Lin, J. H.: Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab. Dispos., 28: 125-130 (2000).
20. Pessayre, D., Larrey, D., Vitaux, J., Breil, P., Belghiti, J. and Benhamou, J. P.: Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochem. Pharmacol., 31: 1699-1704 (1982).
21. Zhou, S. F., Xue, C. C., Yu, X. Q., Li, C. and Wang, G.: Clinically important drug interactions potentially involving mechanismbased inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit., 29: 687-710 (2007).
22. McConn, D.J., Lin, Y. S., Allen, K., Kunze, K. L. and Thummel, K. E.: Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab. Dispos., 32:1083-1091 (2004).
23. Kobayashi, K., Chiba, K., Yagi, T., Shimada, N., Taniguchi, T., Horie, T., Tani, M., Yamamoto, T., Ishizaki, T. and Kuroiwa, T.: Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J. Pharmacol. Exp. Ther., 280: 927-933 (1997).
24. Wang, Y. H., Jones, D. R. and Hall, S.D.: Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab. Dispos., 33: 664-671 (2005).
25. Ekins, S., Stresser, D. M. and Williams, J. A.: In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol. Sci., 24: 161-166 (2003).
26. Wright, M. C., Edward, R. J., Pimenta, M., Ribeiro, V., Ratra, G. S., Lechner, M. C. and Paine, A. J.: Developmental changes in the constitutive and inducible expression of cytochrome P450 3A2. Biochem. Pharmacol., 54: 841-846 (1997).
27. Yanagimoto, T., Itoh, S., Sawada, M. and Kamataki, T.: Mouse cytochrome P450 (Cyp3a11): predominant expression in liver and capacity to activate aflatoxin B1. Arch. Biochem. Biophys., 340: 215-218 (1997).
28. Yanagimoto, T., Itoh, S., Sawada, M., Hashimoto, H. and Kamataki, T.: Molecular cloning and functional expression of a mouse cytochrome P450 (Cyp3a13): examination of Cyp3a-13 to activate aflatoxin B1. Biochem. Biophys. Acta., 1201: 405-410 (1994).